Ligufalimab Biosimilar - Research Grade

Product Code: ICH5252

More Information

Species Reactivity: Human

Target: CD47

Concentration: >1mg/ml

Isotype: Human IgG4 - kappa

Host: CHO Cells

product name H2: Ligufalimab Biosimilar - Research Grade

Antibodies against the same target: Bulk Anti-Human CD47 (B6H12) Antibody (ICH1014), Anti-Mouse CD47 (MIAP301) In Vivo Antibody - Low Endotoxin (ICH1282), Lemzoparlimab Biosimilar - Research Grade (ICH5034), Magrolimab Biosimilar - Research Grade (ICH5036), Letaplimab Biosimilar - Research Grade (ICH5251), Urabrelimab Biosimilar - Research Grade (ICH5961)

Sequence: https://www.imgt.org/mAb-DB/

Buffer: ICH3002

UniProt: Q08722

Shipping Conditions: Blue ice

background: This is a research-grade, unconjugated non-therapeutic recombinant analog of the anti-CD47 antibody ligufalimab, engineered as a human IgG4-kappa built around the CD47 target (UniProt Q08722). It is supplied for research use only and is not the clinical drug, nor is it intended for human or veterinary use. As a functional binder to human CD47, it is useful as a tool reagent for probing the CD47-SIRPalpha "don't eat me" axis in vitro and in preclinical settings: mapping CD47 expression, blocking CD47-SIRPalpha engagement, and serving as a positive/reference control alongside other CD47-directed reagents or in

Products are for research use only. Not for use in diagnostic or therapeutic procedures.
ichorbio, ichorbio logo and all other trademarks are the property of ichorbio LTD © ichorbio 2026

cross-competition assays. The IgG4 framework, which limits Fc effector engagement relative to IgG1, makes it a useful backbone for dissecting blockade-driven versus Fc-driven phagocytosis. Provided at research grade with low endotoxin (1 EU/mg; ultra-low 0.5 EU/mg options), it supports macrophage phagocytosis assays, binding/neutralization characterization, ADCC/ADC-development workflows, and biosimilar comparability studies. Bulk quantities (mg to gram scale) are available to support assay development, screening, and reproducible preclinical experiments. CD47 (integrin-associated protein; UniProt Q08722) is a broadly expressed five-transmembrane cell-surface glycoprotein with a single extracellular IgV-like domain. Its principal counter-receptor is SIRPalpha on macrophages and other myeloid cells; CD47-SIRPalpha ligation delivers an inhibitory "don't eat me" signal that restrains macrophage phagocytosis. Many tumors upregulate CD47 to evade innate immune clearance, making the axis an oncology target. CD47 also binds thrombospondin-1, modulating nitric oxide signaling, vascular tone, and cell adhesion/migration, and it associates in cis with integrins to influence cell spreading and motility. Because CD47 is ubiquitously expressed, including on erythrocytes, target-mediated binding and potential red-cell effects are important considerations when designing and interpreting CD47-directed experiments.

Other names: CD47, IAP, MER6, OA3, CD47 molecule, integrin associated protein

Specificity: Detects human CD47

Purification Method: This monoclonal antibody was purified using Protein A

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity: >95% by SDS-PAGE

Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.
ichorbio, ichorbio logo and all other trademarks are the property of ichorbio LTD © ichorbio 2026

Delivery Time: 4 weeks

Products are for research use only. Not for use in diagnostic or therapeutic procedures.
ichorbio, ichorbio logo and all other trademarks are the property of ichorbio LTD © ichorbio 2026